Literature DB >> 6611347

Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2.

R González-Amaro, J Alcocer-Varela, E Martínez-Cordero, D Alarcón-Segovia.   

Abstract

We studied natural killer cell-mediated (NKCM) activity and its enhancement by interleukin-2 (IL-2) in 15 patients with mixed connective tissue disease (MCTD). The mean baseline NKCM activity of peripheral blood mononuclear cells (MNC) against K562 target cells in the 51Cr release assay was found to be similar to that found in age/sex-matched controls. MCTD patients' cells, however, responded significatively less to IL-2 induction of NKCM than did those of the controls. Using the single-cell agarose NK assay, we found that MCTD patients have a small number of active NK cells that exhibit a high rate of recycling capacity in the baseline state. These preactivated cells could not be stimulated further by IL-2. In two MCTD patients the response to IL-2 was nil, and in the serum from both of them we found an IgM inhibitory factor of such IL-2 induced enhancement. This factor could be absorbed only partially by normal MNC and NK cell-depleted MNC but completely by an IL-2-dependent T-cell line, suggesting that the inhibitory factor may be acting on the IL-2 receptor. These findings seem to be different from those reported in systemic lupus erythematosus and strengthen the notion that MCTD is due to a different immunoregulatory aberration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611347     DOI: 10.1007/bf00915294

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  28 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

Review 2.  Cellular immunity and its regulation in SLE.

Authors:  D Alarcón-Segovia
Journal:  Clin Rheum Dis       Date:  1982-04

Review 3.  Natural killer (NK) cells and their possible roles in resistance against disease.

Authors:  R B Herberman
Journal:  Clin Immunol Rev       Date:  1981

4.  Autologous rosette-forming T cells as the responding cells in human autologous mixed-lymphocyte reaction.

Authors:  R Palacios; L Llorente; D Alarcón-Segovia; A Ruíz-Arguelles; E Díaz-Jouanen
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

5.  The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity.

Authors:  R A Dempsey; C A Dinarello; J W Mier; L J Rosenwasser; M Allegretta; T E Brown; D R Parkinson
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

6.  Human post-thymic precursor cells in health and disease. IX. Immunoregulatory T cell circuits in peripheral blood of patients with rheumatoid arthritis.

Authors:  R Palacios; A Ruíz-Arguelles; D Alarcón-Segovia
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

7.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

8.  Natural killer funciton in systemic lupus erythematosus.

Authors:  T Hoffman
Journal:  Arthritis Rheum       Date:  1980-01

9.  Natural killing in immunodeficient patients.

Authors:  H S Koren; D B Amos; R H Buckley
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

10.  Recycling and target binding capacity of human natural killer cells.

Authors:  M Ullberg; M Jondal
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

Authors:  M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

3.  Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient.

Authors:  A Vidaller; F Guadarrama; L Llorente; J B Méndez; F Larrea; A R Villa; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.